Prognostic Significance of Mean Platelet Volume on Local Advanced Non-Small Cell Lung Cancer Managed with Chemoradiotherapy

Sakin, Abdullah; Seçmeler, Şaban; Arıcı, Serdar; Geredeli, Çağlayan; Yaşar, Nurgül; Demir, Cumhur; Aksaray, Ferdi; Cihan, Şener

doi:10.1038/s41598-019-40589-4

Cited by 17 publications

(20 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“… 3 The complicated interactions between activated platelets and cancer cells lead to tumour growth, aberrant angiogenesis, invasion and metastasis. 4–6 A mounting body of evidence suggests that MPV plays an important prognostic role in various types of tumours, including upper gastrointestinal tumours, 7–14 colorectal cancer, 15 16 lung cancer, 17–19 breast cancer 20–22 and urothelial carcinoma. 23 24 However, the association between MPV level and cancer prognosis has not been comprehensively investigated due to the inevitable heterogeneity of the samples in different studies.…”

Section: Introductionmentioning

confidence: 99%

Prognostic and clinicopathological significance of pretreatment mean platelet volume in cancer: a meta-analysis

Chen

Zhang

et al. 2020

BMJ Open

View full text Add to dashboard Cite

ObjectiveOur study aimed to evaluate the prognostic and clinicopathological significance of pretreatment mean platelet volume (MPV) on cancer by using meta-analysis of published studies.DesignMeta-analysis.Data sourcesRelevant studies available before 22 December 2019 were identified by searching MEDLINE, EMBASE.Eligibility criteriaAll published studies that assessed the prognostic and clinicopathological significance of pretreatment MPV on cancer were included.Data extraction and synthesisStudies were identified and extracted by two reviewers independently. The HR/OR and its 95% CIs of survival outcomes and clinicopathological parameters were calculated.ResultsA total of 38 eligible studies (41 subsets) with 9894 patients with cancer were included in the final meta-analysis. MPV level was not significantly associated with both overall survival (HR 0.98, 95% CI 0.84 to 1.14) and disease-free survival (HR 1.22, 95% CI 0.86 to 1.73) of patients with cancer. Neither advanced nor mixed-stage tumour patients showed significant association between MPV and overall survival (HR 1.36, 95% CI 0.96 to 1.94, HR 0.90, 95% CI 0.74 to 1.09). However, high MPV had the strongest relationship with poor overall survival (HR 2.01; 95% CI 1.08 to 3.41) in gastric cancer, followed by pancreatic cancer (HR 1.54; 95% CI 1.31 to 1.82). Whereas in the subgroup using receiver operating characteristic curve method to define cut-off values, low MPV was significantly related to poor overall survival (HR 0.78, 95% CI 0.64 to 0.95). In addition, MPV had no significant association with age (OR 0.96, 95% CI 0.90 to 1.02), sex (OR 1.04, 95% CI 1.00 to 1.09), depth of cancer invasion (OR 0.90, 95% CI 0.77 to 1.04) and tumour stage (OR 0.91, 95% CI 0.78 to 1.07).ConclusionsPretreatment MPV level is of no clearly prognostic significance in cancers and no significant association with clinicopathological parameters of patients with cancers.

show abstract

Section: Introductionmentioning

confidence: 99%

Prognostic and clinicopathological significance of pretreatment mean platelet volume in cancer: a meta-analysis

Chen

Zhang

et al. 2020

BMJ Open

View full text Add to dashboard Cite

show abstract

“…Lung adenocarcinoma (LUAD), the most frequent subtype of lung cancer, has increased both in incidence and mortality[2]. Though traditional treatments, such as radiotherapy, chemotherapy and radical surgery, have been used clinically, the prognosis is still poor with a 5-year survival rate below 15%[3, 4]. Currently, patients cannot receive timely treatment because there is no effective early diagnostic method[5].…”

Section: Introductionmentioning

confidence: 99%

Function of low ADARB1 expression in lung adenocarcinoma

Wang¹,

Xu²,

Ren³

et al. 2019

PLoS ONE

View full text Add to dashboard Cite

Adenosine deaminase RNA-specific B1 (ADARB1), an adenosine-to-inosine (A-to-I) RNA-editing enzyme, has been found to play an essential role in the development of cancer. However, the specific function of ADARB1 in lung cancer, especially in lung adenocarcinoma (LUAD), is still not fully understood and requires further study. In our study, integrative bioinformatics were used to analyze the detailed function of ADARB1 in LUAD. By conducting bioinformatics analyses of several public databases, such as Gene Expression Profiling Interactive Analysis (GEPIA), GE-mini, and Oncomine, we found significantly decreased ADARB1 expression in LUAD cells and tissues. Moreover, RT-PCR and Western blot showed lower ADARB1 expression in H358 and A549 LUAD cells compared to human bronchial epithelial Beas-2B cells. Wound Healing Assay indicated that knockdown ADARB1 could promote LUAD cell metastasis. By using the Kaplan-Meier Plotter tool, we found that downregulation of ADARB1 was related to shorter first progression (FP), overall survival time (OS) and post-progression survival time (PPS). The relevant clinical data acquired from the Wanderer database indicated that the expression and methylation values of ADARB1 were significantly associated with the clinical characteristics of LUAD. Using DNA methylation inhibitor, we found DNMT inhibitor 5-aza-2-deoxycytidine (5-azaD) could promote the expression of ADARB1 and reverse the inhibition effect of ADARB1 in migration. In addition, functional enrichment analysis of ADARB1-associated coexpression genes was further conducted. Our investigation demonstrated that low levels of ADARB1 were specifically found in LUAD, and this gene might be a potential target in the diagnostic and prognostic evaluation of LUAD patients.

show abstract

“…PDW, MPV, and P-LCR are often used to measure platelet size and as surrogate markers of platelet activation (31). Several studies have reported that high PDW and MPV were poor prognostic markers in various malignancies (32)(33)(34). P-LCR is often reported as a prognostic factor in coronary artery disease and myocardial infarction, but has never been associated with cancer prognoses (35).…”

Section: Discussionmentioning

confidence: 99%

Impact of Antiplatelet and Anticoagulant Therapies on Platelet-related Prognostic Markers in Patients With Esophageal Cancer

Ishibashi

Tsujimoto

Kasahara

et al. 2020

In Vivo

View full text Add to dashboard Cite

Background/Aim: In recent years, platelet-related markers were recognized as useful prognostic factors in various malignancies. We investigated the relationship between platelet-related prognostic markers and anti-platelet or anti-coagulant therapies for survival outcomes in esophageal squamous cell carcinoma. Patients and Methods: Preoperative platelet-related prognostic markers were evaluated from peripheral blood testing and statistical analyses were performed to evaluate the prognostic value of these markers and reveal the effects of antiplatelets and/or anticoagulants regarding their prognostic relevance. Results: In all 176 patients, preoperative platelet-to-lymphocyte ratio (PLR) was not found to be a predictor of overall survival (OS). However, in patients without antiplatelet or anticoagulant therapies, PLR was significantly associated with a poor OS (p=0.03). Although platelet large cell ratio (P-LCR) was not associated with the prognosis in patients with antiplatelet and/or anticoagulant therapies, higher P-LCR was associated with a poor prognosis in patients without antiplatelet or anticoagulant therapies (p<0.0001). Conclusion: Researching detailed antiplatelet and anticoagulant therapies could reinforce the prognostic value of platelet-related prognostic markers in ESCC. Esophageal cancer is the eighth most common diagnosed cancer in the world, with a persistent high mortality rate due to its late-stage diagnosis and rapid progression; the 5-year survival rate ranges from 15% to 25%. Recently, several immunoinflammatory markers, such as the neutrophil-tolymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), and C-reactive protein-to-albumin ratio (CAR), have been reported to have prognostic relevance in various malignancies (1-8). However, several studies have failed to discover the prognostic value of PLR in esophageal cancer (9-11). Although immunoinflammatory markers are easily affected by various factors, such as neoadjuvant chemotherapy (NAC), smoking history, comorbidities, and the use of antiplatelet and anticoagulant drugs, little is known regarding the effect of these factors on the prognostic relevance of immunoinflammatory markers. In recent years, antiplatelet and anticoagulant therapies have been reported to reduce cardiovascular events, and the number of patients taking these drugs has increased (12, 13). The present study aimed to investigate the effect of antiplatelet and anticoagulant drug use on platelet-related prognostic markers such as PLR, platelet distribution width (PDW), mean platelet volume (MPV), and platelet large cell ratio (P-LCR) in patients with resectable esophageal squamous cell carcinoma (ESCC). Patients and Methods Patients. A total of 176 patients diagnosed with ESCC who underwent curative transthoracic esophageal resection at the National Defense Medical College Hospital (Tokorozawa, Japan) from January 2009 to December 2016 were included in the present study. The mean±standard deviation age was 70.1±8.4 years (range=43-90 years). Of the 176 patients, 25 (1...

show abstract

Prognostic Significance of Mean Platelet Volume on Local Advanced Non-Small Cell Lung Cancer Managed with Chemoradiotherapy

Cited by 17 publications

References 25 publications

Prognostic and clinicopathological significance of pretreatment mean platelet volume in cancer: a meta-analysis

Prognostic and clinicopathological significance of pretreatment mean platelet volume in cancer: a meta-analysis

Function of low ADARB1 expression in lung adenocarcinoma

Impact of Antiplatelet and Anticoagulant Therapies on Platelet-related Prognostic Markers in Patients With Esophageal Cancer

Contact Info

Product

Resources

About